Patents Assigned to NOXOPHARM LIMITED
  • Patent number: 11559510
    Abstract: A method for providing a steady state plasma concentration of about 20-400 ng/ml of isoflavonoid compounds comprising the steps of a first rectal administration of the compound in a lipophilic suppository base followed by further rectal administrations no earlier than 4, 8 or 16 hours after the previous rectal administration.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 24, 2023
    Assignee: NOXOPHARM LIMITED
    Inventors: Graham Kelly, Kate Porter
  • Patent number: 11541030
    Abstract: The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: January 3, 2023
    Assignee: NOXOPHARM LIMITED
    Inventors: Graham Kelly, Olivier Laczka, Michael Gantier
  • Publication number: 20220105182
    Abstract: The invention relates to a method for inducing an abscopal response to radiotherapy in an individual.
    Type: Application
    Filed: December 14, 2021
    Publication date: April 7, 2022
    Applicant: NOXOPHARM LIMITED
    Inventor: Graham KELLY
  • Patent number: 11229703
    Abstract: A method for inducing abscopal, complete or partial response to radiotherapy comprising administering isoflavone compounds and irradiating with a cytotoxic dose of ionising radiation so that fewer than all of the plurality of tumours are irradiated.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 25, 2022
    Assignee: NOXOPHARM LIMITED
    Inventor: Graham Kelly
  • Publication number: 20210338576
    Abstract: The invention relates to cancer therapy, especially to cytotoxic agents and chemo-sensitizing and radio-sensitising agents, particularly isoflavonoids, and to improving the bioavailability of same.
    Type: Application
    Filed: May 24, 2021
    Publication date: November 4, 2021
    Applicant: NOXOPHARM LIMITED
    Inventor: Graham KELLY
  • Publication number: 20210299085
    Abstract: The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 30, 2021
    Applicant: NOXOPHARM LIMITED
    Inventors: Graham KELLY, Olivier LACZKA, Michael GANTIER
  • Publication number: 20210275493
    Abstract: A method for improving a response in an individual to immuno-oncology therapy for cancer.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 9, 2021
    Applicant: NOXOPHARM LIMITED
    Inventors: Graham KELLY, Olivier LACZKA
  • Publication number: 20190160004
    Abstract: The invention relates to cancer therapy, especially to cytotoxic agents and chemo-sensitizing and radio-sensitising agents, particularly isoflavonoids, and to improving the bioavailability of same.
    Type: Application
    Filed: July 28, 2016
    Publication date: May 30, 2019
    Applicant: NOXOPHARM LIMITED
    Inventor: Graham KELLY
  • Publication number: 20190117620
    Abstract: A method for treating or preventing cancer including administering to a person in need thereof a first composition including a platin, a taxane, or combination of same and a second composition including an isoflavonoid.
    Type: Application
    Filed: April 21, 2017
    Publication date: April 25, 2019
    Applicant: NOXOPHARM LIMITED
    Inventor: Graham KELLY
  • Publication number: 20190117618
    Abstract: A method for providing a steady state plasma concentration of about 20-400 ng/ml of isoflavonoid compounds comprising the steps of a first rectal administration of the compound in a lipophilic suppository base followed by further rectal administrations no earlier than 4, 8 or 16 hours after the previous rectal administration.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Applicant: NOXOPHARM LIMITED
    Inventors: Graham KELLY, Kate PORTER